bioRxivPlant Biology
Plant-based expression of SARS-CoV-2 antigens for use in an oral vaccine
Abstract
Oral and intra-nasal vaccines represent a key means of inducing mucosal-based immunity against infection with SARS-CoV-2, yet such vaccines represent only a minority of candidates currently in development. In this brief communication, we assessed the expression of the SARS-CoV-2 Receptor Binding Domain (RBD) subunit of the surface-exposed Spike glycoprotein in the leaves of nine edible plant species (lettuce, spinach, collard greens, tomato, cucumber, radish, arugula, pepper, and Coho greens), with a goal of identifying a suitable candidate for the development of an oral vaccine against COVID-19. We report lettuce (Lactuca sativa L. cv. Hilde II Improved) to be a preferred host to support in planta expression of SARS-CoV-2 RBD, representing an important first step towards development of a plant-based oral vaccine.
- organism: plant (other)
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Plant-based production of SARS-CoV-2 antigens for use in a subunit vaccine
J. J. Demone, M. Maltseva, … A. M. MacLean·bioRxiv·Oct 17, 2021
- Engineering, production and characterization of Spike and Nucleocapsid structural proteins of SARS-CoV-2 in Nicotiana benthamiana as vaccine candidates against COVID-19
T. Mammedov, D. Yuksel, … G. Hasanova·bioRxiv·Dec 29, 2020
- Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants
T. Mammedov, D. Yuksel, … G. Hasanova·bioRxiv·Apr 7, 2022
- A Secreted Subunit SARS-CoV-2 RBD-CpE Yeast Oral Vaccine Induces an Adaptive Immune Response in BALB/c Mice
John Donnie Ramos, Christopher Bresnahan, … Nicanor Pier Giorgio Austriaco·bioRxiv·Dec 8, 2025
- Development of a vaccine against the newly emerging COVID-19 virus based on the receptor binding domain displayed on virus-like particles
- An oral vaccine for SARS-CoV-2 RBD mRNA-bovine milk-derived exosomes induces a neutralizing antibody response in vivo